AI assistant
Isracann Biosciences Inc. — Board/Management Information 2023
Jan 24, 2023
46619_rns_2023-01-24_db02591a-a42c-4cdc-adab-a67133129d5b.pdf
Board/Management Information
Open in viewerOpens in your device viewer
Form 51–102F3 MATERIAL CHANGE REPORT
Item 1. Name and Address of Company Isracann Biosciences Inc. (the “ Company ”) 1600 – 595 Burrard Street Vancouver, BC V7X 1L3
Item 2. Date of Material Change January 20, 2023
- Item 3. News Release A news release dated January 20, 2023 was disseminated via Stockwatch and subsequently filed on SEDAR.
Item 4. Summary of Material Change The Company appoints Ajay Singh Kala as the Company’s interim Chief Executive Officer, effective January 20, 2023.
Item 5. Full Description of Material Change 5.1 Full Description of Material Change
The Company announced the appointment of Ajay Singh Kala as the Company’s interim Chief Executive Officer, effective January 20, 2023, following the resignation of Phil Floucault.
5.2 Disclosure for Restructuring Transactions
Not applicable.
- Item 6. Reliance on subsection 7.1(2) of National Instrument 51–102 Not applicable.
Item 7. Omitted Information
None.
- 2 -
Item 8. Executive Officers
The following senior officer of the Company is knowledgeable about the material change and this Material Change Report and may be contacted at:
Yana Popova Chief Financial Officer and Corporate Secretary 604-328-5598 [email protected]
Item 9. Date of Report
January 24, 2023